Autologous skin cell suspensions established by the VeritaCell method accelerate healing and suppress scarring-associated cutaneous thickening in a rat wound model in vivo

This study demonstrates that VeritaCell-derived autologous skin cell suspensions significantly accelerate wound healing and reduce scarring-associated thickening in a rat model, validating their efficacy even at low donor-to-wound ratios and suggesting a promising strategy for treating extensive injuries like burns while minimizing donor skin requirements.

The Gist

The Big Picture: A New Way to Patch Up Wounds

Imagine your skin is like a brick wall. When you get a big cut or a burn, it's like a huge chunk of that wall has been knocked out. Usually, to fix a big hole, you have to take a large chunk of bricks from another part of your own house (a skin graft) and move it over. This works, but it leaves a new hole where you took the bricks, and the patch often looks a bit ugly or scarred.

Scientists have been trying to find a better way: instead of moving a whole chunk of wall, why not just take the bricks (skin cells), mix them in a bucket of water, and spray them onto the hole? This is called Autologous Cell Suspension (ACS). It's like using a "liquid patch."

The problem is, making this "liquid patch" has been slow, expensive, and sometimes the cells die before they hit the wound.

The New Hero: VeritaCell

The researchers in this paper developed a new, super-fast method called VeritaCell. Think of it as a high-speed blender that gently breaks down a tiny piece of healthy skin into a soup of living cells without killing them. They found that this soup contains special "foreman" cells (stem cells) that know exactly how to rebuild the wall.

But does this "cell soup" actually work on a real wound? That's what this study tested.

The Experiment: The Rat "Wall" Test

To test this, the scientists used 32 rats. They created two identical circular holes (wounds) on the back of each rat.

• The Control Group: One wound got just a saline solution (like plain water).
• The Test Groups: The other wounds got the VeritaCell "soup."

Here is the clever part: They didn't just dump the same amount of soup on every wound. They tested three different "concentrations" to see how much donor skin was actually needed:

1. 1:1 Ratio: A lot of cells (like using a whole bucket of bricks for a small hole).
2. 1:10 Ratio: Ten times more wound area than donor skin (like using a cup of bricks for a big hole).
3. 1:20 Ratio: Twenty times more wound area than donor skin (like using a single handful of bricks for a massive hole).

What Happened? (The Results)

1. Speed: The "Soup" Sped Things Up
The wounds treated with the cell soup healed faster. Specifically, by Day 6, the treated wounds were already showing significant signs of closing up, while the plain water wounds were still lagging behind. It's as if the cell soup gave the repair crew a caffeine shot, getting them to work immediately.

2. Quality: The "Soup" Prevented Ugly Scars
This is the most exciting part. When a wound heals poorly, the new skin often grows too thick and bumpy, like a scar that sticks up in the air.

• The Control wounds (plain water) healed, but the new skin was thick, messy, and uneven.
• The 1:10 and 1:20 groups (the diluted soups) healed with skin that was smooth, flat, and looked almost exactly like normal, healthy skin.

The Surprise: You might think that using more cells (the 1:1 ratio) would be best. But surprisingly, it wasn't. The 1:10 ratio was the "Goldilocks" zone—not too much, not too little. It healed the best. It seems that flooding the wound with too many cells might actually confuse the repair process, whereas a moderate amount lets the body's natural healing take the lead.

Why This Matters

1. Less Donor Pain: Because this method works even when you dilute the cells 20 times (1:20 ratio), a doctor only needs to take a tiny scrap of skin from a patient to heal a massive burn. It's like using a single drop of ink to color a whole page.
2. Better Scars: It doesn't just close the wound; it makes the new skin look and feel normal, reducing the risk of ugly, thick scars.
3. Simple and Fast: The VeritaCell method doesn't need fancy, expensive machines. It can be done quickly, even in a hospital room, making it accessible for emergencies like severe burns.

The Bottom Line

This study proves that you don't need a massive skin graft to fix a big wound. By using a special, fast method to turn a tiny piece of skin into a "cell soup," doctors can spray it on a wound to make it heal faster and look much better. It's a shift from "moving a wall" to "spraying a liquid repair kit."

Technical Summary

1. Problem Statement

• Clinical Challenge: Large wounds (e.g., burns, diabetic ulcers) heal slowly, often leading to infection, chronic non-healing states, and significant financial burdens on healthcare systems (estimated at £8.3 billion for the UK NHS alone).
• Limitations of Current Standard of Care: Split-thickness skin grafting (STSG) is the current gold standard but requires large donor sites (1:1 or 1:2 donor-to-wound ratios), leading to donor site morbidity, poor aesthetics, and lengthy hospital stays.
• Limitations of Existing Cell Therapies: While Autologous Cell Suspension (ACS) therapies offer a "point-of-care" solution using minimal donor skin, existing methods suffer from:
  • Inadequate clinical success rates.
  • High costs of proprietary devices.
  • Requirement for complex instrumentation and laboratory conditions.
  • Lack of optimization regarding the donor-to-wound coverage ratio.

2. Methodology

The study evaluated the in vivo efficacy of VeritaCell, a novel, rapid, enzymatic disaggregation method for preparing ACS, using a rat full-thickness excisional wound model.

• Experimental Model:
  • Subjects: 32 male Wistar rats (220–240g).
  • Wound Induction: Two 8mm full-thickness circular wounds were created on the dorsal midline of each rat using a punch biopsy tool.
  • Donor Tissue: A 1–2 cm² split-thickness skin graft (STSG) was harvested from the dorsal skin of each rat prior to wounding.
• Treatment Groups (n=8 per group):
  • Control: Ringer's solution.
  • 1:1 Ratio: Undiluted ACS (1 unit donor skin area per 1 unit wound area).
  • 1:10 Ratio: ACS diluted to cover 10x the donor area.
  • 1:20 Ratio: ACS diluted to cover 20x the donor area.
  • Note: Both wounds on a single rat received the same treatment to avoid cross-contamination.
• Procedure:
  • ACS was prepared using the VeritaCell method (enzymatic disaggregation at room temperature, no specialized instrumentation).
  • 100μL of treatment was applied to wounds on Day 0.
  • Wounds were dressed for 4 days, then left open.
  • Monitoring occurred on Days 0, 4, 6, 8, 10, 12, and 14.
• Assessment Metrics:
  • Macroscopic: Digital imaging and ImageJ analysis to calculate % wound closure rates.
  • Histological: Tissue harvested on Day 14, fixed, and stained with Hematoxylin & Eosin (H&E).
  • Quantitative Histology: Measurement of mean epidermal layer thickness to assess scarring and neo-epithelial organization.

3. Key Contributions

• Validation of VeritaCell: This study provides the first in vivo functional validation of the VeritaCell methodology, confirming that its rapid, room-temperature enzymatic process yields biologically active cell suspensions capable of enhancing wound healing.
• Optimization of Dosage: The study systematically tested donor-to-wound ratios, identifying that lower cell densities (1:10 and 1:20) can be as effective or more effective than high-density applications (1:1), challenging the assumption that "more cells equal better healing."
• Dual Benefit Demonstration: The research demonstrates that VeritaCell ACS not only accelerates the speed of wound closure but also improves the quality of healing by suppressing scarring-associated tissue thickening.

4. Key Results

• Wound Closure Dynamics:
  • Early Acceleration: ACS-treated wounds showed significantly enhanced closure dynamics compared to controls. While the control group showed significant healing only after Day 8, all ACS groups showed significant acceleration by Day 6.
  • Peak Performance: The 1:10 ratio group was the first to exceed 80% wound closure by Day 8.
  • Statistical Significance: Significant within-group improvements were observed in ACS groups by Day 6 (p<0.01 for 1:1; p<0.001 for 1:10 and 1:20), whereas the control group did not show significant improvement until Day 8.
• Histological Findings (Quality of Healing):
  • Control Group: Exhibited dense, disorganized extracellular matrix and extensive, highly variable epidermal thickening (indicative of scarring).
  • ACS Groups: Showed improved neo-epithelial organization and reduced epidermal thickness.
  • The 1:10 Effect: The 1:10 group demonstrated the most favorable outcome, with an epidermal layer that was thinner, less variable, and histologically resembled unwounded skin.
  • The 1:1 Anomaly: Contrary to expectations, the 1:1 (highest cell density) group showed more variability in thickness than the 1:10 group, suggesting that an "overwhelming" number of cells may not be optimal.
• Safety: No signs of inflammation, infection, or wound deterioration were observed in any group.

5. Significance

• Clinical Translation: The findings support the clinical use of VeritaCell ACS for extensive injuries (e.g., burns) where minimizing donor site morbidity is critical. The ability to treat a wound 10 to 20 times larger than the donor site significantly reduces the need for large skin grafts.
• Scarring Reduction: By suppressing scarring-associated cutaneous thickening, this approach offers a pathway to more aesthetically favorable healing outcomes, a major unmet need in burn care.
• Cost-Effectiveness and Accessibility: The VeritaCell method requires no specialized instrumentation and operates at room temperature, making it a potentially low-cost, "point-of-care" solution that could be deployed in resource-limited settings.
• Biological Insight: The results suggest that the therapeutic efficacy of ACS relies not just on cell quantity, but on cell viability and the specific biological activity of the secretome. The "sweet spot" for donor-to-wound ratios appears to be around 1:10, providing a new parameter for optimizing cell-based therapies.

In conclusion, this preclinical study validates VeritaCell as a robust, effective, and scalable technology for enhancing both the speed and quality of wound healing, offering a promising alternative to traditional skin grafting.